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Abstract 
Adipose-derived mesenchymal stem cells (AdMSCs) augment the ability to contribute to 
microvascular remodeling in vivo and to modulate vascular stability in fresh fat grafts. Although 
cryopreserved adipose tissue is frequently used for soft tissue augmentation, the viability of 
the fat graft is poor. The effects of culture-expanded human adipose tissue-derived mesen-
chymal stem cells (hAdMSCs) on the survival and quality of the cryopreserved fat graft were 
determined. hAdMSCs from the same donor were mixed with fat tissues cryopreserved at 
–70°C for 8 weeks and injected subcutaneously into 6-week-old BALB/c-nu nude mice. Graft 
volume  and  weight  were  measured,  and  histology  was  evaluated  4  and  15  weeks 
post-transplantation. The hAdMSC-treated group showed significantly enhanced graft volume 
and weight. The histological evaluation demonstrated significantly better fat cell integrity 
compared with the vehicle-treated control 4 weeks post-transplantation. No significant dif-
ference in graft weight, volume, or histological parameters was found among the groups 15 
weeks post-transplantation. The hAdMSCs enhanced the survival and quality of transplanted 
cryopreserved fat tissues. Cultured and expanded hAdMSCs have reconstructive capacity in 
cryopreserved fat grafting by increasing the number of stem cells. 
Key words: Human adipose tissue-derived mesenchymal stem cells (hAdMSCs), cryopreserved fat 
tissues, viability of fat grafts, dose-dependent. 
Introduction 
Autologous  fat  transplantation  is  used  for  soft 
tissue augmentation in reconstructing various tissue 
defects, primarily congenital or acquired facial anom-
alies,  facial  rejuvenation,  and  cosmetic  breast  aug-
mentation in plastic surgery [1-3]. Although aspirated 
fat tissue is a safe natural filler with a natural texture, 
softness,  and  contour,  there  are  some  associated 
problems, including unpredictability and a low rate of 
graft  survival  owing  to  partial  necrosis.  Magnetic 
resonance  imaging  studies  have  indicated  that  the 
resorption rate in clinical use is 55–70% of the injected 
volume [4]. 
Many clinical methods have been developed to 
enhance  the  viability  and  improve  the  survival  of 
transplanted fat tissue [2, 3, 5-7]. Tissue-specific pro-




pose-derived  stem/stromal  cells  or  adipose  tis-
sue-derived mesenchymal stem cells (AdMSCs), have 
the capacity to differentiate into various cell lineages 
[8] and clinically enhance the viability and effective-
ness of fat grafts [2, 3, 9]. To increase the viablity of fat 
grafts,  it  is  important  to  minimize  the  reabsorption 
rate and to prevent the necrosis of transplanted fat by 
promoting the growth of new blood vessels [9-13]. 
The capacity of AdMSCs to secrete multiple bi-
oactive angiogenic and anti-apoptotic growth factors 
has stimulated interest in the clinical application of 
these cells. As AdMSCs can be obtained in sufficient 
numbers in vitro, it may be possible to use cultured 
AdMSCs  to  clinically  enhance  the  viability  of  fat 
grafts  without  the  need  for  harvesting  cells  from  a 
large volume of liposuction aspirate. 
In this study, we investigated the effects of hu-
man adipose tissue-derived mesenchymal stem cells 
(hAdMSCs) on the survival of fat grafts in mice. The 
hAdMSCs were mixed with cryopreserved fat tissue 
and injected into nude mice. The retained fat weight 
and volume, and the graft histology were evaluated. 
Materials and Methods 
Animals 
Six-week-old male BALB/c-nu nude mice (Ori-
ent Bio, Gyonggi-Do, Korea) weighing 13–17 g were 
used in the experiments. The animals were kept under 
controlled  environmental  conditions  with  constant 
laminar airflow, temperature of 20–23°C, and humid-
ity of 40-60%, and a 12/12-h light/dark cycle. They 
were given access to standard laboratory chow and 
sterilized water ad libitum. 
All experiments were conducted in accordance 
with the Guide for the Care and Use of Laboratory 
Animals of Jeju National University. 
Preparation of hAdMSCs from aspirated human 
fat tissues 
Informed  consent  was  obtained  for  the  use  of 
human  adipose  tissues.  Human  aspirated  fat  tissue 
was obtained by liposuction and was separated from 
fluids and cell debris by centrifugation. The aspirated 
fat tissue was frozen directly with liquid nitrogen and 
stored at –70°C for 8 weeks until used for transplan-
tation experiments. 
To  prepare  hAdMSCs,  subcutaneous  adipose 
tissues were digested with 4 mL of RTase cell isolation 
enzyme (RNL BIO, Seoul, Korea) per gram of fat un-
der gentle agitation for 60 min at 37°C. The digested 
tissues were filtered through a 100-μm nylon sieve to 
remove cellular debris and were collected by centrif-
ugation at 1500 rpm for 5 min. The pellet was resus-
pended in RCME cell attachment medium (RNL BIO) 
containing  10%  fetal  bovine  serum  (FBS).  After  an-
other  centrifugation  at  1500  rpm  for  5  min,  the  su-
pernatant was discarded, and the pellet was collected. 
The cells were cultured overnight at 37°C in 5% CO2 
in  RCME  containing  10%  FBS.  Cell  adhesion  was 
examined  under  an  inverted  microscope  24  h  later. 
Non-adherent cells were removed after 24 h, the ad-
herent cells were washed with PBS, and the medium 
was  changed  to  RKCM  cell  growth  medium  (RNL 
BIO) containing 5% FBS. The cells were maintained 
for 4–5 days until confluent (passage 0) and then ex-
panded in RKCM until passage 3 at 90% confluence. 
The  immunophenotypes  of  the  AdMSCs  were  ana-
lyzed using a FACSCalibur flow cytometer (BD Bio-
sciences, Franklin Lakes, NJ) and CellQuest software. 
Every harvest of hAdMSCs revealed a homogenous 
population of cells with the characteristics of mesen-
chymal stem cells. The cells expressed mesenchymal 
stem cell markers, including CD90, CD105, CD44, and 
CD29, and did not express hematopoietic or endothe-
lial markers (CD31, CD34, and CD45). Cell viability 
evaluated by trypan blue exclusion before transplan-
tation was greater than 95%. No evidence of bacterial, 
fungal, or mycoplasmal contamination was observed. 
The  procedure  for  hAdMSC  preparation  was  per-
formed  using  good  manufacturing  practices  in  the 
Stem Cell Research Center of RNL BIO (Seoul, Korea). 
Fat transplantation 
Fat aspirates and hAdMSCs from the same do-
nor  were  used  in  the  experiments.  A  mixture  con-
taining 1 mL of the cryopreserved fat tissue and 300 
µL  of  phosphate-buffered  saline  (PBS)  containing 
1 × 106 (n = 6) or 1 × 107 hAdMSCs (n = 6) was injected 
subcutaneously over the skulls of the mice. PBS was 
used as a vehicle control (n = 6). 
Follow-up and data collection 
The animals were euthanized at 4 or 15 weeks 
after fat transplantation. No animals died during the 
study.  The  remaining  grafted  fat  tissues  were  dis-
sected out and weighed, and their volumes were de-
termined by the liquid overflow method [7]. Briefly, a 
graduated cylinder was filled with distilled water, the 
dissected fat tissues were immersed in the cylinder, 
and the fat volume was determined by the consequent 
increase  in  the  water  level.  Histological  evaluations 
were  performed  by  a  professional  pathologist  in  a 
blinded  manner.  Each  slide  was  evaluated  for  the 
presence of [7, 14]: 1) intact and nucleated fat cells; 
2) cysts and vacuoles; 3) inflammation, as evidenced 
by the infiltration of lymphocytes and macrophages; 
and 4) fibrosis and other components of connective 




to 5 as follows: absent, 0; minimal presence, 1; mini-
mal  to  moderate  presence,  2;  moderate  presence,  3; 
moderate  to  extensive  presence,  4;  and  extensive 
presence, 5. 
Statistical analysis 
The Mann-Whitney rank-sum test was used to 
compare  the  fat  weight,  fat  volume,  and  fat  tissue 
histological parameters among the groups. All statis-
tical  analyses  were  performed  using  SPSS  software 
(ver.  17.0E;  SPSS,  Seoul,  Korea).  For  differences  be-
tween  the  hAdMSC-treated  and  control  groups, 
p-values  less  than  0.05  were  considered  to  indicate 
statistical significance. 
Results 
The weight and volume of the remaining grafted 
fat tissue were determined at 4 and 15 weeks after fat 
transplantation. Animals were selected at random and 
sacrificed at each time point (each n = 6). 
At  4  weeks  after  transplantation,  a  significant, 
dose-dependent  increase  in  the  survival  of  cryo-
preserved  fat  grafts  was  observed  in  the  groups 
treated  with  hAdMSCs  compared  with  the  vehi-
cle-treated  control  group  (Table  1).  There  were  no 
significant differences among the groups at 15 weeks 
after transplantation. 
At  4  weeks  post-transplantation,  histological 
evaluations  of  the  transplanted  fat  tissues  stained 
with  hematoxylin  and  eosin  revealed  significantly 
better fat cell integrity in the hAdMSC-treated mice 
compared with vehicle-treated controls (P < 0.05; Ta-
ble  2).  There  were  no  significant  differences  in  the 
other histological parameters, including cyst/vacuole 
formation,  inflammation,  and  fibrosis,  among  the 
groups. At 15 weeks post-transplantation, none of the 
histological parameters differed significantly among 




Table 1. Comparison of fat graft weight and volume with vehicle and hAdMSCs transplantation. 
    Fat weight (g)  Fat volume (mL) 
Transplantation    4 weeks P.T.  15 weeks P.T.  4 weeks P.T.  15 weeks P.T. 
Vehicle-control  PBS  0.13 ± 0.12  0.22 ± 0.27  0.18 ± 0.21  0.22 ± 0.24 
hAdMSCs   1 × 106 cells  0.2 ± 0.2  0.11 ± 0.13  0.28 ± 0.22  0.13 ± 0.14 
1 × 107 cells  0.5 ± 0.23*†  0.19 ± 0.14  0.48 ± 0.24‡  0.24 ± 0.14 
Data are expressed as means ± SD. P.T., post-transplantation 
*P < 0.05 vs. vehicle-treated control 
†P < 0.05 vs. treatment with 1 × 106 hAdMSCs 




Table 2. Comparison of the histological evaluations with vehicle and hAdMSC transplantation. 
    Integritya  Cyst/Vacuolesa  Inflammationa  Fibrosisa 
Transplantation    4 wks P.T.  15  wks 
P.T. 
4 wks P.T.  15  wks 
P.T. 
4  wks 
P.T. 
15  wks 
P.T. 
4  wks 
P.T. 
15  wks 
P.T. 
Vehicle-control  PBS  3.2 ± 0.8  2.2 ± 1.6  1.5 ± 0.8  1.6 ± 0.9  1.2 ± 1.6  2.4±1.7  1.2±0.8  1.0 ± 1.7 
hAdMSCs   1 × 106 cells  4.2 ± 0.4*  2.8 ± 0.8  1.5 ± 0.5  1.7 ± 1.0  0.5 ± 0.5  2.5±1.2  0.7±0.5  2.5 ± 1.4 
1 × 107 cells  4.5 ± 0.8*  3.8 ± 0.4  0.5 ± 0.5  1.7 ± 0.5  0.3 ± 0.5  1.8±1.5  0.3±0.5  1.8 ± 1.2 
Data are expressed as means ± SD. P.T., post-transplantation 
a Scale: 0, absent; 1, minimal presence; 2, minimal to moderate presence; 3, moderate presence; 4, moderate to extensive presence; 5, extensive 
presence 
*P < 0.05 vs. vehicle-treated control 
 
 





The dissected fat grafts in the control group were 
weaker  and  more  fragile  than  those  in  the 
hAdMSC-treated  groups  at  4  weeks 
post-transplantation (Fig. 1A–F). In two of the six ve-
hicle-treated controls, the dissected fat graft contained 
blood-like  liquid  at  15  weeks  post-transplantation 
(Fig. 2B and 2C). In the other vehicle-treated controls, 
little  of  the  fat  explants  remained,  and  they  were 
composed  of  connective  tissue.  At  4  weeks 
post-transplantation,  the  fat  grafts  in  the 
hAdMSC-treated mice (1 × 106 and 1 × 107 cells) were 
readily dissected and were yellowish (Fig. 1G–R). At 
15 weeks post-transplantation, the fat explants were 
darker yellow in mice treated with 1 × 106 hAdMSCs 
(Fig. 2G–L) compared with mice treated with 1 × 107 
hAdMSCs  (Fig.  2M–R).  There  were  no  side  effects 
such as the presence of blood-like liquid in any indi-
vidual mouse treated with hAdMSCs. 
Fat  necrosis  and  fibrosis  were  observed  in  the 
control group at 4 weeks after fat transplantation (Fig. 
3A).  Despite  very  mild  inflammation  and  cyst  for-
mation in the group treated with 1 × 106 hAdMSCs, 
the fat grafts in the hAdMSC-treated groups were in 
better condition than those in the control group (Fig. 
3B). Adipocytes showed a homogeneous distribution 
in the group treated with 1 × 107 hAdMSCs (Fig. 3C). 
Massive fat necrosis and remaining acidophilic 
ghost-like cells were observed in histological sections 
of the control group at 15 weeks after fat transplanta-
tion.  Irregularly  sized  necrotic  fat  cells  were  sur-
rounded  by  thick  progressive  fibrosis  at  15  weeks 
post-transplantation  (Fig.  3D).  Many  infiltrating 
polymorphonuclear cells were present in this fibrotic 
band. Mild inflammatory cell infiltration and fibrosis 
were  observed  in  the  group  treated  with  1 × 106 
hAdMSCs  (Fig.  3E).  The  distribution  of  adipocytes 
was  more  homogeneous  in  the  mice  treated  with 
1 × 107 hAdMSCs (Fig. 3F) than in those treated with 
1 × 106 cells (Fig. 3E). Very mild fibrosis was also seen 





Figure 1. The fat explants from individual mice harvested at 4 weeks post-transplantation. A–F, vehicle-treated control 
group. G–L, 1 × 10
6 hAdMSC-treated group. M–R, 1 × 10





Figure 2. The fat explants from individual mice harvested at 15 weeks post-transplantation. A–F, vehicle-treated control 
group. G–L, 1 × 10
6 hAdMSC-treated group. M–R, 1 × 10
7 hAdMSC-treated group. Scale bar = 50 mm. 
 
 
Figure 3. Histological features of fat grafts at 4 (A–C) and 15 (D–F) weeks post-transplantation (H & E staining). A and D, 
vehicle-treated control group. B and E, 1 × 10
6 hAdMSC-treated group. C and F, 1 × 10
7 hAdMSC-treated group. All images 
were taken at 100× magnification. A) Fat necrosis and fibrosis (arrowheads) are seen in the vehicle-treated control group. 
B) Slight inflammation (arrows) and cyst formation are visible in the 1 × 10




(arrows) is seen in the 1 × 10
7 hAdMSCs treated group. D) Irregularly sized necrotic fat cells are surrounded by thick 
progressive fibrosis (star) at 15 weeks post-transplantation. Many polymorphonuclear cells (PMNs) had infiltrated the 
fibrotic band. Massive fat necrosis is visible, and acidophilic ghosts remain (※). E) Progressive fibrosis (star) is evident, and 
some inflammatory cells (arrows) have infiltrated in the 1 × 10
6 hAdMSC-treated group. F) Slight fibrosis (arrows) is seen in 
the 1 × 10
7 hAdMSC-treated group. 
 
Discussion 
Adipose tissue has been used as an autologous, 
natural filler for soft tissue defects because antigenic 
and  allergic  reactions  are  minimized.  Given  these 
advantages, autologous fat transplantation is a useful 
technique in plastic and reconstructive surgery. Clin-
cally, adipose tissues are taken from the belly or thigh 
by liposuction as this simple procedure reduces the 
stress to the patient. However, compared with non-
suctioned adipose tissues, suctioned fat tissues con-
tain  fewer  multipotent  AdMSCs  and  a  majority  of 
impaired  adipocytes,  because  of  the  centrifugation 
step used to concentrate and separate adipocytes from 
the debris, including blood cells, lipids, proteases, and 
other components [15-19]. The relative deficiency of 
mutipotent AdMSCs contributes to the unpredictable 
partial absorption, low survival rate, and long-term 
atrophy  of  transplanted  lipoaspirates,  and  repeated 
lipotransplantation is often necessary [2, 3, 18, 20]. 
To address these issues, many clinical methods 
have been tried to enhance the viability and survival 
rate of transplanted fat tissues [2, 3, 5-7]. Several re-
ports have demonstrated that grafted fat has an in-
creased  survival  rate  when  transplanted  with  the 
stromal  vascular  fraction  (i.e.,  AdMSCs)  obtained 
from  alternative  liposuction  aspirates  enriched  in 
AdMSCs  [2,  3,  18,  20].  This  strategy,  termed 
cell-assisted lipotransfer (CAL), has proven to be ef-
fective, safe, and superior to conventional lipoinjec-
tion used in procedures such as breast reconstruction, 
cosmetic breast augmentation, and facial lipoatrophy 
[2,  3].  However,  the  efficiency  of  CAL  in  terms  of 
survival duration of engrafted fats still shows  indi-
vidual variation. 
Another  way  to  increase  the  efficiency  of  fat 
transplantation  is  repeated  fat  transplantation  with 
cryopreserved adipose tissues, which avoids repeated 
surgery to obtain fresh fat tissue. Although adipose 
tissues  cryopreserved  under  improved  conditions 
gave relatively better results compared with simply 
cryopreserved fat, the results were still less satisfac-
tory than those with fresh adipose tissues [21, 22]. 
Accordingly,  in  this  study,  we  applied  cryo-
preserved  aspirated  fats  and  culture-expanded  hu-
man AdMSCs, because it is difficult to obtain a suffi-
cient number of mesenchymal stem cells from aspi-
rated  fat  with  minimal  manipulation.  The  average 
number of AdMSCs isolated per gram of aspirated fat 
without expansion culture is 73,000 ± 24,700 cells [12]. 
In  the  present  study,  part  of  the  aspirated  fat  was 
processed to culture AdMSCs, and the remaining fat 
was stored at –70°C until used for transplantation at 
about 8 weeks. We transplanted human fat tissue over 
the skulls of nude mice, which have little to no en-
dogenous  fat,  thereby  minimizing  the  chance  of 
measuring  endogenous  mouse  fat  instead  of  trans-
planted human fat. Furthermore, the skull has a rela-
tively low blood supply and thus a lower level of fat 
retention than other sites, including the back, abdo-
men, and leg muscles, in recipient animals [23]. 
Our  results  demonstrated  that  cultured 
hAdMSCs improved the quality and viability of im-
planted adipose tissue, with no central necrosis of the 
transplanted fat tissue and reduced inflammation and 
fibrosis.  In  this  study,  transplanted  fat  tissue  was 
frozen  directly  without  any  cryoprotectant,  which 
resulted in few or no adipose stem cells in the trans-
planted fat tissue, because viable adipose stem cells 
were not harvested from directly frozen adipose as-
pirates [24]. Our results indicate that expanded Ad-
MSCs provide a reconstructive capacity in aspirated 
fat  grafting  by  supplementing  the  number  of  stem 
cells. After three or four passages in our culture sys-
tem, more than one billion cells could be easily ob-
tained from less than 10 g of fat  tissue. The use  of 
cultured  AdMSCs  can  be  beneficial  when  sufficient 
AdMSCs cannot be obtained via the minimal manip-
ulation of aspirated fat. In addition, because cultured 
AdMSCs  increase  the  viability  of  transplanted  fat 
tissues,  their  use  can  minimize  the  amount  of  fat 
needed for mammoplasty, which usually requires a 
large fat graft. Given that there were no differences 
between the stem cell and control groups at 15 weeks 
in the present study, additional studies investigating 
the effects of AdMSCs on the duration of graft sur-
vival are needed. 
Although the mechanism of action of AdMSCs in 
a  reconstructive  capacity  was  not  evaluated  here, 
many previous studies have demonstrated that Ad-
MSCs contribute to increased microvascular density, 
accelerated neoangiogenesis, and adipocyte differen-
tiation, while preventing apoptosis by producing and 
releasing soluble angiogenic factors such as vascular 




and insulin-like growth factor-1 [12, 13, 23]. The ca-
pacity of culture-expanded hAdMSCs [25] and other 
reported AdMSCs [10, 12, 13, 23] to differentiate into 
endothelial cells in vitro supports their contribution to 
neoangiogenesis. 
In conclusion, culture-expanded AdMSCs have 
the capacity to increase fat graft survival and may be 
beneficial  to  patients  without  producing  the  addi-
tional stress associated with obtaining more adipose 
tissue or performing repeated liposuction. 
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